CDMO Wheeler Bio appoints Jay Benson as chief operating officer
He joins the US company with over two decades of experience in pharma operations, supply chain and manufacturing.
List view / Grid view
He joins the US company with over two decades of experience in pharma operations, supply chain and manufacturing.
He arrives at the Netherlands-based contract research organisation from TFS HealthScience.
The planned succession will also see him become Chair of the German pharma company’s Executive Board in May 2026.
In a surprise announcement, she will be replaced at the UK pharma company by its Chief Commercial Officer Luke Miels.
He takes over at the CRO from Peter Benton and brings experience from GHO Capital, Syneos Health and INC Research.
David Weinreich will also serve as its Chief Medical Officer and arrives at the German pharmaceutical group with experience from Amgen, Bayer and Regeneron.
The biopharmaceutical company’s executive transition follows a multi-year succession process to support its next chapter.
The new executive recruits at Amgen and Pfizer will support advancement in therapeutic areas including oncology and rare disease.
The new member of Genmab’s Executive Committee brings over 30 years of international biopharmaceutical experience to the role.
Following the appointment, Thomas Hudson, AbbVie’s current Senior Vice President, Chief Scientific Officer, Global Research, will retire.
The new Executive Vice President (EVP) has over “25 years of experience and a proven track record of leading strategic quality initiatives”, Eli Lilly and Company shared.
The new Executive Vice President of Teva Global Operations will bring “significant experience at every stage of the manufacturing and supply process” to his new role, the company asserted.
The incoming CEO of the contract development and manufacturing organisation (CDMO) Lonza will transition into his new role over Summer 2024.
An ex-Biogen executive has been appointed as CDMO FUJIFILM Diosynth Biotechnologies’ new Chief Quality Officer.
Former Senior Vice President, Head of Research and Product Development of Alexion, will succeed Mene Pangalos as Executive Vice President, BioPharmaceuticals R&D at AstraZeneca.